Clinical Trial Update: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Ampligen plus standard of care versus standard of care alone for locally advanced pancreatic cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Ampligen (rintatolimod)

Snippet

Sponsor: AIM ImmunoTech Inc. | Conditions: Pancreatic Cancer | Phase 2 | Status: SUSPENDED